Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts

Trial Profile

A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Hydrogen peroxide (Primary)
  • Indications Warts
  • Focus Therapeutic Use
  • Acronyms THWART-2
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 06 Nov 2018 According to an Aclaris Therapeutics media release, Topline data are expected in the second half of 2019.
    • 24 Sep 2018 According to an Aclaris Therapeutics media release, First Patient Dosed in this study.
    • 24 Sep 2018 According to an Aclaris Therapeutics media release,Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top